Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* healthy male~* ≥18 to ≤45 years old~* Body mass index (BMI) between 18-30 kg/m² inclusive~* Written informed consent to participate.~Main Exclusion Criteria:~* Any clinically relevant acute or chronic diseases~* Any history of drug or alcohol abuse~* Any History of clinical significant disease as determined by medical history, physical examination or other evaluations.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- MOTREM 1 (Type: EXPERIMENTAL): None
- MOTREM 2 (Type: EXPERIMENTAL): None
- MOTREM 3 (Type: EXPERIMENTAL): None
- MOTREM 4 (Type: EXPERIMENTAL): None
- MOTREM 5 (Type: EXPERIMENTAL): None
- MOTREM 6 (Type: EXPERIMENTAL): None
- MOTREM 7 (Type: EXPERIMENTAL): None
- MOTREM 8 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).